Barbui T., Cortelazzo S., Galli M. et al. Antiphospholipid antibodies in early repeated abortions: a case-controlled study. Fertil Steril1988; 50: 589-92.
2.
Creagh MD, Malia RG, Cooper SM, Smith AR, Duncan Slb, Greaves M.Screening for lupus anticoagulant and anticardiolipin antibodies in women with fetal loss. J Clin Pathot1991; 44: 45-7.
3.
Ramsey-Goldman R, Kutzer JE, Kuller LH, Guzick D., Betts Carpenter A., Medsger TA Jr. Pregnancy outcome and anti-cardiolipin antibody in women with systemic lupus erythematosus . Am J Epidemiol1993; 138:1057-69.
4.
Infante-Rivard C., David M., Gauthier R., Rivard GELupus anticoagulant, anticardiolipin antibodies and fetal loss. A case-control study. New Engl J Med1991; 325: 1063-6.
5.
Ginsberg JS, Brill-Edwards P., Johnston M. et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood1992; 80: 975-80.
6.
Alarcon-Segovia D., Deleze M., Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus . Medicine1989; 68: 353-65.
7.
Harris EN, Chan Jkh, Asherson RA, Aber VR, Gharavi AE, Hughes Grv.Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med1986; 146: 2153-6.
8.
Lockwood CJ, Romero R., Feinberg RF, Clyne LP, Coster B., Hobbins JCThe prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol1989 ; 161: 369-73.
Lynch A., Marlar R., Murphy J. et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med1994; 120: 470-6.
11.
Out HJ, Bruinse HW, Christiaens Gcml et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol1992; 167: 26-32.
12.
Lockshin MD , Druzin ML, Goei S. et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus . New Engl J Med1985; 313: 152-6.
13.
Englert HJ, Derue GM, Loizou S. et al. Pregnancy and lupus: prognostic indicators and response to treatment . Q J Med1988; 66: 125-36.
14.
Lubbe WF, Palmer SJ, Butler WS, Liggins GCFetal survival after prednisone suppression of maternal lupus anticoagulant . Lancet1983; i: 1361,
15.
Branch DW, Scott JR, Kochenour NK, Hershgold E.Obstetric complications associated with lupus anticoagulant. New Engl J Med1985; 313: 1322-6.
16.
Rosove MH, Tabsh K., Wasserstrum N., Howard P., Hahn BH, Kalunian KCHeparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol1990; 75: 630-4.
17.
Silveira LH , Hubble CL, Jara LJ et al. Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin . Am J Med1992; 93: 403-11.
18.
Lockshin MD , Druzin ML, Qamar T.Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibodies. Am J Obstet Gynecol1989 ; 160: 439-43.
19.
Cowchock FS, Reece EA, Balaban D., Branch DW, Plouffe L.Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol1992; 166: 1318-23.
20.
Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A.Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol1993; 169: 1411-17.
21.
The Antiphospholipid Antibodies in Stroke Study Group (APASS).Clinical, radiological, and pathological aspects of cerebrovascular disease associated with antiphospholipid antibodies . Stroke1993; 24 (Suppl. I): I-120-I-123.
22.
Barbui T., Finazzi G., Cortelazzo S., Galli M., Camerlingo M.A case-control estimate of the relative risk of cerebral ischemic disease in young subjects with antiphospholipid antibodies. Thromb Haemost1989; 62: 584.
23.
Long AA, Ginsberg JS, Brill-Edwards P. et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus. Thromb Haemost1991; 66: 520-4.
24.
Ginsberg KS , Liang MH, Newcomber L. et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med1992; 117: 997-1002.
25.
Ordi J., Selva A., Monegal F., Porcel JM, Martinez-Costa X., Vilardell M.Anticardiolipin antibodies and dependence of a serum cofactor. A mechanism of thrombosis. J Rheumatol1993 ; 20: 1321-4.
26.
Galli M., Comfurius P., Maassen P. et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet1990 ; 335: 1544-7.
27.
Levine SR, Brey RL, Joseph Clm, Havstad S. on behalf of the APASS.Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke1992 ; 23 (Suppl. I): 1-29-1-32.
28.
Vianna JL, Khamashta MA, Ordi-Ros J. et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med1994; 96: 3-9.
29.
Italian Registry of Antiphospholipid Antibodies (IR-APA).Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematological1993; 78: 313-18.
30.
Hamsten A., Bjorkholm M., Norberg R., deFaire U., Holm G.Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular event. Lancet1986; i: 113-16.
31.
Sltenes KE, Smith P., Abedlnoor M., Arnesen H., Wisloff F.Antiphospholipid antibodies after myocardial infarction and their relation to morality, reinfarction and non-haemorrhagic stroke. Lancet1992; 339: 451-3.
32.
Phadke KV, Phillips RA, Clarke Dtr, Jones M., Naish P., Carson P.Anticardiolipin antibodies in ischemic heart disease: marker or myth?Br Heart J1993; 69: 391-4.
33.
Raghavan C. , Ditchfield J., Taylor RJ, Haeney MR, Barnes PCInfluence of anticardiolipin antibodies on immediate patient outcome after myocardial infarction. J Clin Pathol1993; 46: 1113-15.
34.
Cortellaro M., Boschetti M., Cardillo M., Barbui T.Antiphospholipid antibodies in patients with previous myocardial infarction. Lancet1992 ; 339:929-30.
Rosove MH, Brewer Pmc.Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med1992; 117: 303-8.
37.
Cortelazzo S., Finazzi G., Viero P. et al. Thrombotic and haemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemos1993; 69: 316-20.
38.
Orlando E., Cortelazzo S., Marchetti M., Sanfratello R., Barbui T.Prolonged bleeding time in patients with lupus anticoagulant. Thromb Haemost1992; 68: 495-9.
39.
Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DBA mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood1983; 61: 684-92.
40.
Babikian VL , Levine SRTherapeutic considerations for stroke patients with antiphospholipid antibodies. Stroke1992 ; 23 (Suppl.I): I-33-I-37.
41.
Lechner K., Pabinger-Faching I.Lupus anticoagulant and thrombosis. A study of 25 cases and review of the literature. Haemostasis1985; 15: 254-62.
42.
Singleton D. , Conyers L.Warfarin and azathioprine: an important drug interaction. Am J Med1992; 92: 217.
43.
Rivier G., Khamashta MA, Hughes Grv.Warfarin and azathioprine: a drug interaction does exist. Am J Med1993; 95: 342.
44.
Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central vein catheters: a randomized prospective trial. Ann Intern Med1990; 112: 423-8.
45.
Levine M., Hirsh J., Gent M. et al. Double-blind randomised trial of very-low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet1994; 343: 886-9.
46.
Poller L., McKeman A., Thomson JM, Elstein M., Hirsch PJ, Jones JBFixed mini-dose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J1987 ; 70: 343-50.
47.
Antiplatelet Trialist' Collaboration.Collaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J1994; 308: 81-106.
48.
Antiplatelet Trialist' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J1994; 308: 235-46.
49.
Exner T., Triplett DA, Taberner D., Machin SJGuidelines for testing and revised criteria for lupus anticoagulants . Thromb Haemost1991; 65:320-2.